U.S. markets closed

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
5.68+0.10 (+1.79%)
At close: 4:00PM EST

6.25 +0.57 (10.04%)
After hours: 7:56PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Down

Gap Down

Performance Outlook
Previous Close5.58
Open5.64
Bid5.58 x 800
Ask6.50 x 900
Day's Range5.53 - 5.88
52 Week Range2.18 - 9.79
Volume76,612
Avg. Volume219,253
Market Cap263.552M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • What Kind Of Investors Own Most Of Kezar Life Sciences, Inc. (NASDAQ:KZR)?
    Simply Wall St.

    What Kind Of Investors Own Most Of Kezar Life Sciences, Inc. (NASDAQ:KZR)?

    The big shareholder groups in Kezar Life Sciences, Inc. ( NASDAQ:KZR ) have power over the company. Large companies...

  • Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference
    Business Wire

    Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference

    Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the BIO CEO & Investor Digital Conference, being held from February 16 – 18, 2021. Kezar’s Chief Scientific Officer, Chris Kirk, Ph.D., will participate in a panel discussion, "Progress in Drugging the Undruggable Cancer Targets" at the conference.

  • Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
    Business Wire

    Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference

    Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, being held on January 11-14, 2021.